Premium
Growth response to cytokines of circulating myeloid progenitors from myelodysplastic patients at diagnosis and more than 600 days after diagnosis
Author(s) -
Tennant Graham B.,
Bowen David T.,
Jacobs Allan
Publication year - 1991
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1991.tb00563.x
Subject(s) - myelodysplastic syndromes , granulocyte macrophage colony stimulating factor , colony stimulating factor , myeloid , immunology , interleukin 3 , granulocyte colony stimulating factor , medicine , macrophage colony stimulating factor , progenitor cell , cfu gm , granulocyte , growth factor , macrophage , cytokine , biology , in vitro , bone marrow , haematopoiesis , stem cell , chemotherapy , immune system , t cell , biochemistry , receptor , antigen presenting cell , genetics
Myeloid colony growth from the peripheral blood of myelodysplastic (MDS) patients was assessed for abnormal in vitro response to haemopoietic growth factors (granulocyte colony‐stimulating factor (G‐CSF), macrophage colony‐stimulating factor (M‐CSF), granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), interleukin‐1 (IL‐l), interleukin‐3 (IL‐3)). Abnormal colony growth, increased or reduced, was observed with each of the factors. No specific growth pattern was related to any of the French‐American‐British classification (FAB) types of disease. MDS patients who had survived >600 days after diagnosis (n = 34) showed significantly fewer abnormalities than patients assayed at the time of diagnosis (n = 37), the major difference being less frequent stimulation of colony growth. These findings indicate that the time of sampling relative to diagnosis needs to be considered when interpreting the in vitro response to growth factors of myeloid colonies from MDS patients.